Medicover AB (5M0B) Stock Price & Analysis
5M0B Stock Chart & Stats
- Day’s Range
- EUR 25.10 - EUR 25.45
- 52-Week Range
- EUR 16.74 - EUR 25.45
- Previous Close
- EUR 25.20
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 3.93B
- Enterprise Value
- EUR 50.31B
- Total Cash (Recent Filing)
- EUR 92.70M
- Total Debt (Recent Filing)
- EUR 1.46B
- Price to Earnings (P/E)
- 46.0
- Beta
- 0.69
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 0.17
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.78%
Bulls Say, Bears Say
Bulls Say
Organic Revenue Growth
Double-digit organic growth across Healthcare and Diagnostics indicates broad demand and continued expansion of Medicover’s operating platform. Sustained volume growth can improve network utilization, deepen customer relationships, and support further earnings growth over the next several quarters.
Margin And ROIC Expansion
Improving EBIT margins and ROIC show that revenue growth is increasingly translating into more productive operations rather than only higher scale. Six consecutive quarters of margin improvement and acquisition synergies support the durability of current profitability gains.
Cash Generation And Deleveraging
Strong operating cash flow, positive free cash flow, and falling leverage improve Medicover’s ability to fund expansion while servicing debt. Reaching sub-3x leverage also increases financial flexibility and supports management’s medium-term growth and investment targets.
Bears Say
Elevated Leverage
Although leverage is improving, debt remains high relative to equity and reduces financial flexibility during a downturn or higher-rate environment. Elevated obligations may constrain discretionary investment, increase sensitivity to weaker cash generation, and limit room for unexpected pressures.
India Start-up Losses
The Indian hospital rollout is producing strong growth but currently weighs on consolidated margins while new facilities mature. Continued investment and ramp-up losses could delay profitability improvement, particularly if patient volumes or doctor recruitment develop more slowly than expected.
Reimbursement And Membership Pressure
Membership weakness and changing government-funded payment systems create structural uncertainty for revenue mix and profitability in affected markets. Tariff caps, budget changes, or wage-policy shifts could increase reliance on fee-for-service activity and make planning less predictable.
Medicover AB News
5M0B FAQ
What was Medicover AB’s price range in the past 12 months?
What is Medicover AB’s market cap?
When is Medicover AB’s upcoming earnings report date?
How were Medicover AB’s earnings last quarter?
Is Medicover AB overvalued?
Does Medicover AB pay dividends?
What is Medicover AB’s EPS estimate?
How many shares outstanding does Medicover AB have?
What happened to Medicover AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medicover AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Medicover AB
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- John Paul Stubbington
- Employees
- 49,000
- Website
- www.medicover.com
- Address
- Riddargatan 12A, Stockholm, AB, 102 46, SE
Medicover AB (5M0B) Earnings & Revenues
5M0B Earnings Call
Earnings Call SentimentPositive
The call presents a broadly positive performance: double-digit organic revenue growth, continued margin expansion across multiple quarters, strong cash generation, reduced leverage under 3x, Diagnostics and India showing robust top-line momentum, and management reaffirming mid-term targets. Key challenges include start-up losses from new Indian hospitals (EUR 3.2m this quarter), some healthcare margin dilution from tough comparables, membership declines in Romania, and political/reimbursement uncertainties in certain markets. Overall, positive operational and financial trends outweigh the manageable headwinds.
View all DE:5M0B earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
